The results show that depletion of CD8+ cells abrogated anti-tumor effects of G47Δ-mIL12 treatment, as demonstrated by similar tumor growth kinetics and tumor free survival as mock-treated animals (Figures 5E,F). This evidence concerns the gene CD8A and neoplasm.